Under the agreement, Antyra will obtain exclusive rights to develop and commercialize certain IGF antagonists discovered during the research and license collaboration agreement entered into between the companies in December 2001.
IGF, or insulin-like growth factor, is a natural growth promoting entity, the blockage of whose action has attracted attention as a potential anticancer therapy for the treatment of many solid tumors. Financial terms of the agreement were not disclosed.
Neil Goldstein, president and chief scientific officer of Antyra, said: “We are very happy to conclude this arrangement with Novo Nordisk. We believe that the company has generated some exciting data with several of the IGF-1R antagonists and they represent a novel and potentially effective clinical strategy for the treatment of pancreatic and other cancers.”